Evidence map›Paper›PMID 35885667›Full record

ArticleDiagnostics (Basel, Switzerland)2022

A Simple, Cost-Effective, and Extraction-Free Molecular Diagnostic Test for Sickle Cell Disease Using a Noninvasive Buccal Swab Specimen for a Limited-Resource Setting.

Priya Thakur, Pragya Gupta, Nupur Bhargava, Rajat Soni, Narendra Varma Gottumukkala, Sangam Giri Goswami, Gaurav Kharya, Vinodh Saravanakumar, Padma Gunda, Suman Jain and 3 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Priya ThakurCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.
Pragya GuptaCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.
Nupur BhargavaCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.
Rajat SoniCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.
Narendra Varma GottumukkalaCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.ORCID 0000-0001-5394-0520
Sangam Giri GoswamiCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.
Gaurav KharyaIndraprastha Apollo Hospitals, Sarita Vihar, New Delhi 110020, India.
Vinodh SaravanakumarCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.
Padma GundaThalassemia and Sickle Cell Society, Rajendra Nagar, Hyderabad 500052, India.
Suman JainThalassemia and Sickle Cell Society, Rajendra Nagar, Hyderabad 500052, India.
Jasmita DassDepartment of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Mukul AggarwalDepartment of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Sivaprakash RamalingamCSIR-Institute Genomics and Integrative Biology, Mathura Road, Sukhdev Vihar, New Delhi 110025, India.ORCID 0000-0002-0901-2513

Funding

Council for Scientific and Industrial Research MLP2010 and HCP023Department of Biotechnology BT/GET/119/SP31652/2020
6 · The paper itself

Abstract

Sickle cell disease (SCD) is the most prevalent life-threatening blood monogenic disorder. Currently, there is no cure available, apart from bone marrow transplantation. Early and efficient diagnosis of SCD is key to disease management, which would make considerable strides in alleviating morbidity and reducing mortality. However, the cost and complexity of diagnostic procedures, such as the Sanger sequencing method, impede the early detection of SCD in a resource-limited setting. To address this, the current study demonstrates a simple and efficient proof-of-concept assay for the detection of patients and carriers using extraction-free non-invasive buccal swab samples by isothermal DNA Amplification coupled Restrictase-mediated cleavage (iDAR). This study is a first of its kind reporting the use of buccal swab specimens for iDA in molecular diagnosis of a genetic disease, all the while being cost effective and time saving, with the total assay time of around 150 min at a cost of USD 5. Further, iDAR demonstrates 91.5% sensitivity and 100% specificity for detecting all three alleles: SS, AS, and AA, having a 100% concordance with Sanger sequencing. The applicability of the iDAR assay is further demonstrated with its adaptation to a one-pot reaction format, which simplifies the assay system. Overall, iDAR is a simple, cost-effective, precise, and non-invasive assay for SCD screening, with the potential for use in a limited resource setting.

Indexed as

buccal swabextraction-freeisothermal DNA amplificationmolecular diagnostic testnon-invasivesickle cell disease

Identifiers

PMID35885667
PMCPMC9318149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.